Bayer AG NA (0P6S.L)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases, as well as collaboration with Bicycle Therapeutics to develop bicyclic peptides. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Company Info
| ISIN | DE000BAY0017 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
Highlights
| Market Cap | €51.70B |
|---|---|
| Revenue (TTM) | €47.64B |
| Gross Profit (TTM) | €31.85B |
| EBITDA (TTM) | €11.33B |
| Year Range | €24.96 - €58.71 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: 0P6S.L vs. CF
Performance
Performance Chart
The chart shows the growth of an initial investment of €10,000 in Bayer AG NA, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Bayer AG NA had a return of -20.14% year-to-date (YTD) and -53.62% in the last 12 months. Over the past 10 years, Bayer AG NA had an annualized return of -10.68%, while the S&P 500 had an annualized return of 10.55%, indicating that Bayer AG NA did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -20.14% | 6.33% |
| 1 month | 0.04% | -2.81% |
| 6 months | -34.48% | 21.13% |
| 1 year | -53.62% | 24.56% |
| 5 years (annualized) | -14.65% | 11.55% |
| 10 years (annualized) | -10.68% | 10.55% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -13.81% | -2.48% | 0.35% | |||||||||
| 2023 | -10.19% | -10.88% | -22.90% | 7.41% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
Bayer AG NA(0P6S.L)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Bayer AG NA (0P6S.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Bayer AG NA granted a 8.92% dividend yield in the last twelve months. The annual payout for that period amounted to €2.40 per share.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | €2.40 | €2.40 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €2.70 | €2.50 | €2.25 | €2.10 | €1.90 |
Dividend yield | 8.92% | 7.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% | 2.59% | 1.97% | 1.89% | 1.87% |
Monthly Dividends
The table displays the monthly dividend distributions for Bayer AG NA. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | €0.00 | €0.00 | €0.00 | |||||||||
| 2023 | €0.00 | €0.00 | €0.00 | €0.00 | €2.40 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2022 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2021 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2020 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2019 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2018 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2017 | €0.00 | €0.00 | €0.00 | €0.00 | €2.70 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2016 | €0.00 | €0.00 | €0.00 | €0.00 | €2.50 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2015 | €0.00 | €0.00 | €0.00 | €0.00 | €2.25 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2014 | €0.00 | €0.00 | €0.00 | €2.10 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| 2013 | €1.90 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Bayer AG NA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bayer AG NA was 81.79%, occurring on Mar 13, 2003. Recovery took 256 trading sessions.
The current Bayer AG NA drawdown is 79.11%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -81.79% | Jan 29, 2001 | 106 | Mar 13, 2003 | 256 | Mar 23, 2007 | 362 |
| -79.87% | Apr 14, 2015 | 2243 | Mar 19, 2024 | — | — | — |
| -47.33% | Jan 15, 2008 | 295 | Mar 17, 2009 | 435 | Dec 7, 2010 | 730 |
| -37.26% | May 9, 2011 | 97 | Sep 22, 2011 | 184 | Jul 2, 2012 | 281 |
| -28.41% | Mar 11, 1997 | 157 | Oct 28, 1997 | 148 | Apr 16, 1999 | 305 |
Volatility
Volatility Chart
The current Bayer AG NA volatility is 8.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |